Samsung Medical Center: Carcinoma, Non-Small-Cell Lung trials

The registry lists 34 Carcinoma, Non-Small-Cell Lung studies with Samsung Medical Center as lead sponsor. 4 are open to participants now and 1 have results posted.

Phase 2 16Phase 3 7Phase 4 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral NeuropathyRecruitingNCT07774520Phase 2
• Anesthesia and Non-small Cell Lung Cancer RecurrenceRecruitingNCT06330038Phase 4
• Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung CancerRecruitingNCT05260606
• Cell Free DNA for the Diagnosis and Treatment in Early NSCLCRecruitingNCT03791034
• Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain MetastasesCompletedNCT04967417Phase 2Results posted
• Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung CancerStatus unknownNCT05377788
• Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic TumorStatus unknownNCT04932343
• Central Nervous System(CNS) Efficacy of DacomitinibStatus unknownNCT04675008Phase 2
• Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer SurgeryActive, not recruitingNCT04536675Phase 3
• Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLCStatus unknownNCT03991403Phase 3
• Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 InhibitorsStatus unknownNCT03656094Phase 2
• Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLCStatus unknownNCT03616691Phase 2
• Uncommon EGFR AZD9291Status unknownNCT03424759Phase 2
• The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR MutationStatus unknownNCT03399669Phase 2
• Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMSStatus unknownNCT03257124Phase 2
• Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDXCompletedNCT03134456Phase 4
• Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung CancerActive, not recruitingNCT03066297
• Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer PatientsStatus unknownNCT03053856Phase 2
• A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKIStatus unknownNCT03050437Phase 2
• Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or GefitinibCompletedNCT02747953Phase 2
• Vandetanib in Advanced NSCLC With RET RearrangementCompletedNCT01823068Phase 2
• Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA AnalysisStatus unknownNCT01776684Not applicable
• Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving ChemotherapyCompletedNCT01482182
• Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase ExpressionStatus unknownNCT01401192Phase 2
• Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)Status unknownNCT01312337Phase 2
• Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain MetastasisStatus unknownNCT01301560Phase 3
• The Continuation of ErlotinibStatus unknownNCT01130779Phase 2
• Asymptomatic Brain Metastasis in Non-small Cell Lung Cancer (NSCLC)Status unknownNCT01130766Phase 3
• Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC)CompletedNCT01079520Not applicable
• Adjuvant CCRT vs CT in Minimal N2 NSCLCCompletedNCT01066234Phase 2
• Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyStatus unknownNCT01066195Phase 3
• Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT01065415
• Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung CancerWithdrawnNCT00329472Phase 3
• Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung CancerCompletedNCT00326378Phase 3